UBE2I and ovarian carcinoma: As demonstrated by us earlier, the Ubc9 binding mutants fail to bind Ubc9, lack E3 Ubiquitin ligase activity, fail to suppress the growth of ovarian cancer cells and are mislocalized in the cytoplasm of ovarian cancer cells [34].